Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
DMKPQ Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: December 06, 2023
Report Source: 2023 3rd Quarter Report
DMK Pharmaceuticals Corp. Stock Analysis DMKPQ
United States Health Care Nano Cap Report: DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. The company is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Read More DMK Pharmaceuticals Corp (DMKPQ) Chart
Financial Metrics & Statements of DMK Pharmaceuticals Corp (DMKPQ)
FAQ's for DMK Pharmaceuticals Corp (DMKPQ)
- According to Musaffa’s Shariah screening methodology, DMK Pharmaceuticals Corp (DMKPQ) is currently classified as NOT HALAL as of December 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes DMK Pharmaceuticals Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in DMK Pharmaceuticals Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of DMK Pharmaceuticals Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of DMK Pharmaceuticals Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of DMK Pharmaceuticals Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.